05 Feb Althea Technologies to produce lead drug for Quintessence
Madison, Wis. – Althea Technologies, Inc., a San Diego-based drug manufacturer, has entered into a manufacturing supply agreement to produce the first drug candidate of the Madison-based Quintessence Biosciences.
The drug candidate, QBI-139, has proven to be effective in fighting cancer in vivo against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors, and could soon advance to human clinical trials.
In the first quarter of 2008, Quintessence plans to file an investigational new drug application with the U.S. Food and Drug Administration, and Althea will provide protein production and purification services to produce the clinical trial materials.
Related stories
• Two federal grants support Quintessence Biosciences
• Quintessence Biosciences projects 2008 clinical trials for lead cancer drug
• Quintessence Biosciences advances cancer drug